The real lesson in the FDA's latest GLP-1 warning letters is net impression
The FDA's June wave of warning letters over compounded GLP-1 marketing turns on net impression, the same standard that decides whether any wellness brand's page is misleading.
During the week of June 15, the FDA sent 25 warning letters to telehealth companies over how they market compounded GLP-1 products. It was the third wave in under a year, after roughly 80 letters last September and another 30 in March. If you sell anything health-adjacent online, the specific drug is not the point. The reasoning behind the letters is.
Every letter turns on a single idea the agency calls net impression. The FDA does not just read your claims one sentence at a time and check each for literal accuracy. It reads the whole page the way a customer would, and asks what overall impression that page creates. Under that standard, a statement that is technically true can still make your marketing misleading if the page as a whole leaves the wrong idea in someone’s head.
The examples the FDA flagged make the standard concrete. Calling a compounded product a “generic” version of a brand-name drug. Saying it contains the “exact same active ingredient” in a way that implies it is the same product. Describing it as “clinically proven” to work like the approved version. Claiming it came from an “FDA-approved” or “FDA-licensed” pharmacy, when the FDA does not approve or license pharmacies that way. Branding the product with your own company’s name and logo so it looks like you manufactured it. None of these requires an outright lie. Each one nudges the customer toward believing something the seller cannot back up, and that nudge is the violation.
This is why I tell health and wellness operators to stop auditing their marketing claim by claim. A legal review that clears each sentence in isolation will miss exactly what regulators are trained to see. The FTC runs the same play on supplement and wellness advertising that the FDA runs here. Both agencies care about the message a reasonable consumer walks away with, including the message your testimonials, before-and-after photos, trust badges, and product names carry on their own. Fine print at the bottom rarely cures an impression the top of the page already created.
The developer version of this is familiar. You can pass every unit test and still ship a product that behaves wrong, because the bug lives in how the pieces combine, not in any single function. Marketing pages fail the same way. The individual claims check out, and the assembled page tells a story you cannot support.
The concrete thing to do this quarter is a net-impression review of your top-selling product pages and your highest-traffic ad creative. Pull up each page and ask one question: if a skeptical regulator read only this, with no context, what would they believe about approval, endorsement, and proven results? Write down every impression the page creates, not just the sentences you wrote on purpose, and then confirm you can substantiate each one. The claims you never literally made are the ones most likely to get you a letter.